不同糖耐量状态下老年男性患者血FABP4与颈动脉内膜中层厚度的相关性
|
摘要
目的探讨不同糖耐量状态下老年男性患者血清中FABP4水平变化及与颈动脉内膜中层厚度(CIMT)的相关性。方法选择新诊断T2DM患者52例,IGT患者40例、正常对照组(NGT)37例,采用ELISA方法检测血浆中FABP4水平,比较不同组间各脂代谢指标及CIMT的差异。结果血清FABP4在3组间呈现组间递增趋势,NGT(23.47±5.74)ng/m L、IGT(27.10±12.25)ng/m L、T2DM(33.68±15.14)ng/m L(P<0.05);CIMT在3组间亦呈递增趋势,NGT(0.93±0.28)mm、IGT(1.01±0.36)mm、T2DM(1.27±0.30)mm(P<0.05)。Pearson相关性分析显示,FABP4与SBP、BMI、WHR、TG、LDL-C、FPG、FINS、HOMA-IR、CIMT均呈正相关(P<0.01)。多元线性逐步回归分析显示,血清FABP4与CIMT、BMI、DBP、HOMA-IR独立相关(P<0.01)。结论老年男性人群血中FABP4与颈动脉硬化密切相关,加剧糖脂代谢紊乱发生。
Objective To investigate the relationships between plasma adipocyte fatty acidbinding protein( FABP4) levels and carotid intima media thickness( CIMT) in elderly male patients with impaired glucose tolerance and type 2 diabetes. Methods A total of 129 elderly men were divided into three groups: normal glucose tolerance( NGT),impaired glucose tolerance( IGT) and type 2diabetes( T2DM). The levels of FABP4 were measured by enzyme-linked immunosorbent assay( ELISA). The associations between FABP4 and carotid intima media thickness were analyzed. Results Fasting FABP4 levels were higher in T2 DM group [( 33. 68 ± 15. 14) ng / m L ]and IGT[( 27.10 ± 12. 25) ng / m L]group than in NGT group[( 23. 47 ± 5. 74) ng / m L]( P < 0. 05). CIMT gradually increased among the three groups( P < 0. 05). There were significant positive correlation respectively between FABP4 and systolic pressure( SBP),body mass index( BMI),waist-hip ratio( WHR),triglyerides( TG),low density lipoprotein cholesterol( LDL-C),fasting plasma glucose( FPG),fasting insulin( FINS),insulin resistance index homeostasis model assessment( HOMA-IR)and CIMT( P < 0. 01). Multiple linear regression analysis indicated that CIMT,BMI,DBP and HOMA-IR were the independent factors affecting FABP4( all P < 0. 01). Conclusion FABP4 level may be associated with CIMT in elderly male patients,and aggravate the disorders of glucose and lipid metabolism.
Objective To investigate the relationships between plasma adipocyte fatty acidbinding protein( FABP4) levels and carotid intima media thickness( CIMT) in elderly male patients with impaired glucose tolerance and type 2 diabetes. Methods A total of 129 elderly men were divided into three groups: normal glucose tolerance( NGT),impaired glucose tolerance( IGT) and type 2diabetes( T2DM). The levels of FABP4 were measured by enzyme-linked immunosorbent assay( ELISA). The associations between FABP4 and carotid intima media thickness were analyzed. Results Fasting FABP4 levels were higher in T2 DM group [( 33. 68 ± 15. 14) ng / m L ]and IGT[( 27.10 ± 12. 25) ng / m L]group than in NGT group[( 23. 47 ± 5. 74) ng / m L]( P < 0. 05). CIMT gradually increased among the three groups( P < 0. 05). There were significant positive correlation respectively between FABP4 and systolic pressure( SBP),body mass index( BMI),waist-hip ratio( WHR),triglyerides( TG),low density lipoprotein cholesterol( LDL-C),fasting plasma glucose( FPG),fasting insulin( FINS),insulin resistance index homeostasis model assessment( HOMA-IR)and CIMT( P < 0. 01). Multiple linear regression analysis indicated that CIMT,BMI,DBP and HOMA-IR were the independent factors affecting FABP4( all P < 0. 01). Conclusion FABP4 level may be associated with CIMT in elderly male patients,and aggravate the disorders of glucose and lipid metabolism.
引文
[1]Boord J B,Maeda K,Makowski L,et al.Combined adipoeyte macrophage fatty acid-binding protein deficiency improves metabolism,atherosclemsis,and survival in apolipoprotein Edeficient mice[J].Circulation,2004,110(11):1492.
[2]Smith A J,Sanders M A,Thompson B R,et al.Physical association between the adipocyte fatty acid-binding protein and hormone-sensitive lipase:a fluorescence resonance energy transfer analysis[J].J Bid Chem,2004,279(50):52399.
[3]Elmasri H,Karaaslan C,Teper Y,et al.Fatty acid binding protein 4 is a target of VEGF and a regulator of cell proliferation in endothelial cells[J].FASEB J,2009,23(11):3865.
[4]Yang R,Castriota G,Chen Y,et al.RNAi-mediated germLine knockdown of FABP4 increases body weight but does not improve the deranged nutrient metabolism of diet-induced obese mice[J].Int J Obes,2011,35(2):217.
[5]Bianchi C,Miccoli R,Penno G,et al.Primary prevention of cardiovascular disease in people with dysglycemia[J].Diabetes Care,2008,31(Suppl 2):S208.
[6]Park S W,Kim S K,Cho Y W,et al.Insulin resistance and carotid atherosclerosis in patients with type 2 diabetes[J].Atherosclerosis,2009,205(1):309.
[7]Terra X,Quintero Y,Auguet T,et al.FABP4 is associated with inflammatory markers and metabolic syndrome in morbidly obese women[J].Eur J Endocrinol,2011,164:539.
[8]Tso AW,Xu A,Sham PC,et al.Serum adipocyte fatty acid binding protein as a new biomarker predicting the development of type 2 diabetes:a 10-year prospective study in a Chinese cohort[J].Diabetes Care,2007,30(10):2667.
[9]CabréA,Lázaro I,Girona J,et al.Plasma fatty acid-binding protein 4 increases with renal dysfunction in type 2 diabetic patients without microalbuminuria[J].Clin Chem,2008,54(1):181.
[10]CabréA,Babio N,Lázaro I,et al.FABP4 predicts atherogenic dyslipidemia development.The PREDIMED study[J].Atherosclerosis,2012,222(1):229.
[11]Yeung DC,Xu A,Cheung C W,et al.Serum adlpocyte fatty acid-binding protein levels were independently associated with carotid therosclerosis[J].Arterioscler Thromb Vasc Biol,2007,27(8):1796.
[12]Fu Y,Luo N,Lopes-Virella M F,et al.The adipocy lipid binding protein(ALBP/a P2)gene facilitates foam cell formati in human THP-1 macrophages[J].Atherosclerosis,2002,165(2):259.
[13]Furuhashi M,Tuncman G,Grgün C Z,et al.Treatment of diabetes and athemscleresis by inhibiting fatty-acid-binding protein a P2[J].Nature,2007,447(7147):959.
[14]Aragonès G,FerréR,Lázaro I,et al.Fatty acid-binding protein 4 is associated with endothelial dysfunction in patients with type 2 diabetes[J].Atherosclerosis,2010,213(1):329.
[15]Aragonès G,FerréR,Girona J,et al.Small artery dilation and endothelial markers in cardiovascular risk patients[J].Eur J Clin Invest,2012,42(1):34.
[16]Saint-Geniez M,Ghelfi E,Liang X L,et al.Fatty Acid Binding Protein 4 Deficiency Protects against Oxygen-Induced Retinopathy in Mice[J].PLo S ONE,2014,9(5):E96253.
[2]Smith A J,Sanders M A,Thompson B R,et al.Physical association between the adipocyte fatty acid-binding protein and hormone-sensitive lipase:a fluorescence resonance energy transfer analysis[J].J Bid Chem,2004,279(50):52399.
[3]Elmasri H,Karaaslan C,Teper Y,et al.Fatty acid binding protein 4 is a target of VEGF and a regulator of cell proliferation in endothelial cells[J].FASEB J,2009,23(11):3865.
[4]Yang R,Castriota G,Chen Y,et al.RNAi-mediated germLine knockdown of FABP4 increases body weight but does not improve the deranged nutrient metabolism of diet-induced obese mice[J].Int J Obes,2011,35(2):217.
[5]Bianchi C,Miccoli R,Penno G,et al.Primary prevention of cardiovascular disease in people with dysglycemia[J].Diabetes Care,2008,31(Suppl 2):S208.
[6]Park S W,Kim S K,Cho Y W,et al.Insulin resistance and carotid atherosclerosis in patients with type 2 diabetes[J].Atherosclerosis,2009,205(1):309.
[7]Terra X,Quintero Y,Auguet T,et al.FABP4 is associated with inflammatory markers and metabolic syndrome in morbidly obese women[J].Eur J Endocrinol,2011,164:539.
[8]Tso AW,Xu A,Sham PC,et al.Serum adipocyte fatty acid binding protein as a new biomarker predicting the development of type 2 diabetes:a 10-year prospective study in a Chinese cohort[J].Diabetes Care,2007,30(10):2667.
[9]CabréA,Lázaro I,Girona J,et al.Plasma fatty acid-binding protein 4 increases with renal dysfunction in type 2 diabetic patients without microalbuminuria[J].Clin Chem,2008,54(1):181.
[10]CabréA,Babio N,Lázaro I,et al.FABP4 predicts atherogenic dyslipidemia development.The PREDIMED study[J].Atherosclerosis,2012,222(1):229.
[11]Yeung DC,Xu A,Cheung C W,et al.Serum adlpocyte fatty acid-binding protein levels were independently associated with carotid therosclerosis[J].Arterioscler Thromb Vasc Biol,2007,27(8):1796.
[12]Fu Y,Luo N,Lopes-Virella M F,et al.The adipocy lipid binding protein(ALBP/a P2)gene facilitates foam cell formati in human THP-1 macrophages[J].Atherosclerosis,2002,165(2):259.
[13]Furuhashi M,Tuncman G,Grgün C Z,et al.Treatment of diabetes and athemscleresis by inhibiting fatty-acid-binding protein a P2[J].Nature,2007,447(7147):959.
[14]Aragonès G,FerréR,Lázaro I,et al.Fatty acid-binding protein 4 is associated with endothelial dysfunction in patients with type 2 diabetes[J].Atherosclerosis,2010,213(1):329.
[15]Aragonès G,FerréR,Girona J,et al.Small artery dilation and endothelial markers in cardiovascular risk patients[J].Eur J Clin Invest,2012,42(1):34.
[16]Saint-Geniez M,Ghelfi E,Liang X L,et al.Fatty Acid Binding Protein 4 Deficiency Protects against Oxygen-Induced Retinopathy in Mice[J].PLo S ONE,2014,9(5):E96253.